tradingkey.logo

OraSure Technologies Inc

OSUR
2.410USD
+0.020+0.84%
收盘 12/22, 16:00美东报价延迟15分钟
174.16M总市值
亏损市盈率 TTM

OraSure Technologies Inc

2.410
+0.020+0.84%

关于 OraSure Technologies Inc 公司

OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company improves the access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers. Its products and services include OraQuick ADVANCE Rapid HIV1/2 Antibody Test, OraQuick HIV Self-Test, and Diagnostics Direct Syphilis Health Check.

OraSure Technologies Inc简介

公司代码OSUR
公司名称OraSure Technologies Inc
上市日期Nov 17, 1986
CEOEglinton Manner (Carrie)
员工数量501
证券类型Ordinary Share
年结日Nov 17
公司地址220 E First St
城市BETHLEHEM
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编18015
电话15036416115
网址https://www.orasure.com/
公司代码OSUR
上市日期Nov 17, 1986
CEOEglinton Manner (Carrie)

OraSure Technologies Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
448.46K
-2.72%
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
160.25K
+1.33%
Mr. John P. Kenny
Mr. John P. Kenny
Independent Chairman of the Board
Independent Chairman of the Board
153.32K
+4.16%
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
+93.09%
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+109.45%
Ms. Anne Messing
Ms. Anne Messing
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Robert W. Mcmahon
Mr. Robert W. Mcmahon
Independent Director
Independent Director
--
--
Mr. Jason Plagman
Mr. Jason Plagman
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Steven K. (Steve) Boyd
Mr. Steven K. (Steve) Boyd
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
448.46K
-2.72%
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
160.25K
+1.33%
Mr. John P. Kenny
Mr. John P. Kenny
Independent Chairman of the Board
Independent Chairman of the Board
153.32K
+4.16%
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
+93.09%
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+109.45%
Ms. Anne Messing
Ms. Anne Messing
Chief Commercial Officer
Chief Commercial Officer
--
--

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Net product and services revenues - COVID-19
14.40M
46.09%
Net product and services revenues - HIV
9.86M
31.54%
Net product and service revenues -Molecular Products
4.13M
13.21%
Other revenues - Other non Product revenues
1.40M
4.47%
Net product and services revenues - Risk assessment testing
994.00K
3.18%
其他
474.00K
1.52%
地区USD
名称
营收
占比
United States
19.85M
63.54%
Africa (Region)
8.03M
25.69%
Europe
2.12M
6.78%
Other Regions
1.25M
3.99%
业务
地区
业务USD
名称
营收
占比
Net product and services revenues - COVID-19
14.40M
46.09%
Net product and services revenues - HIV
9.86M
31.54%
Net product and service revenues -Molecular Products
4.13M
13.21%
Other revenues - Other non Product revenues
1.40M
4.47%
Net product and services revenues - Risk assessment testing
994.00K
3.18%
其他
474.00K
1.52%

股东统计

更新时间: 11月15日 周六
更新时间: 11月15日 周六
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
7.81%
Private Management Group, Inc.
7.55%
Neuberger Berman, LLC
5.86%
The Vanguard Group, Inc.
5.76%
Altai Capital Management, L.P.
5.21%
其他
67.80%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
7.81%
Private Management Group, Inc.
7.55%
Neuberger Berman, LLC
5.86%
The Vanguard Group, Inc.
5.76%
Altai Capital Management, L.P.
5.21%
其他
67.80%
股东类型
持股股东
占比
Investment Advisor
36.59%
Investment Advisor/Hedge Fund
27.60%
Hedge Fund
23.49%
Individual Investor
6.13%
Research Firm
2.26%
Pension Fund
0.47%
Bank and Trust
0.29%
Venture Capital
0.11%
Insurance Company
0.04%
其他
3.02%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
451
66.91M
93.28%
-15.50M
2025Q2
473
72.08M
98.55%
-16.70M
2025Q1
483
70.23M
93.78%
-12.52M
2024Q4
475
70.81M
94.94%
-10.37M
2024Q3
471
70.30M
94.28%
-10.80M
2024Q2
477
73.05M
98.74%
-8.54M
2024Q1
473
74.45M
97.36%
-5.59M
2023Q4
464
73.29M
99.74%
-5.62M
2023Q3
456
72.50M
98.73%
-4.51M
2023Q2
452
70.73M
96.51%
-2.77M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
5.43M
7.43%
-141.00K
-2.53%
Jun 30, 2025
Private Management Group, Inc.
5.46M
7.47%
+1.04M
+23.64%
Jun 30, 2025
Neuberger Berman, LLC
4.16M
5.68%
-124.14K
-2.90%
Jun 30, 2025
The Vanguard Group, Inc.
4.17M
5.7%
-120.08K
-2.80%
Jun 30, 2025
Altai Capital Management, L.P.
3.75M
5.13%
+1.59M
+73.37%
Sep 02, 2025
Dimensional Fund Advisors, L.P.
3.84M
5.25%
+14.96K
+0.39%
Jun 30, 2025
Systematic Financial Management, L.P.
2.23M
3.05%
+581.93K
+35.33%
Jun 30, 2025
Renaissance Technologies LLC
2.28M
3.11%
-294.84K
-11.47%
Jun 30, 2025
Acadian Asset Management LLC
2.19M
3%
-563.24K
-20.44%
Jun 30, 2025
Millennium Management LLC
1.23M
1.69%
+28.80K
+2.39%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Invesco NASDAQ Future Gen 200 ETF
0.44%
iShares US Small Cap Value Factor ETF
0.12%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.05%
iShares Micro-Cap ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
Avantis US Small Cap Equity ETF
0.02%
WisdomTree US SmallCap Fund
0.02%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
DFA Dimensional US Small Cap Value ETF
0.01%
查看更多
Invesco NASDAQ Future Gen 200 ETF
占比0.44%
iShares US Small Cap Value Factor ETF
占比0.12%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
占比0.05%
iShares Micro-Cap ETF
占比0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.04%
Avantis US Small Cap Equity ETF
占比0.02%
WisdomTree US SmallCap Fund
占比0.02%
ProShares UltraPro Russell2000
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
DFA Dimensional US Small Cap Value ETF
占比0.01%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

OraSure Technologies Inc的前五大股东是谁?

OraSure Technologies Inc 的前五大股东如下:
BlackRock Institutional Trust Company, N.A.持有股份:5.43M,占总股份比例:7.43%。
Private Management Group, Inc.持有股份:5.46M,占总股份比例:7.47%。
Neuberger Berman, LLC持有股份:4.16M,占总股份比例:5.68%。
The Vanguard Group, Inc.持有股份:4.17M,占总股份比例:5.70%。
Altai Capital Management, L.P.持有股份:3.75M,占总股份比例:5.13%。

OraSure Technologies Inc的前三大股东类型是什么?

OraSure Technologies Inc 的前三大股东类型分别是:
BlackRock Institutional Trust Company, N.A.
Private Management Group, Inc.
Neuberger Berman, LLC

有多少机构持有OraSure Technologies Inc(OSUR)的股份?

截至2025Q3,共有451家机构持有OraSure Technologies Inc的股份,合计持有的股份价值约为66.91M,占公司总股份的93.28%。与2025Q2相比,机构持股有所增加,增幅为-5.27%。

哪个业务部门对OraSure Technologies Inc的收入贡献最大?

在FY2025Q2,Net product and services revenues - COVID-19业务部门对OraSure Technologies Inc的收入贡献最大,创收14.40M,占总收入的46.09%。
KeyAI